Fact CheckerSign in

NCT05630521Completed

Testing Feasibility of Medication Adherence Problem Solving for Hypertension

Testing Feasibility of the Medication Adherence Problem Solving for Hypertension (MASH) Intervention to Improve Antihypertensive Medication Adherence

Source: ClinicalTrials.gov · Last updated 2 Oct 2024

Brief summary (registry, in English)

Adherence to medications for high blood pressure is key to improving blood pressure control and reducing the impact of cardiovascular disease. This project will test the feasibility of a tailored telehealth intervention to help patients improve adherence to blood pressure medication.

Status (registry)
Completed
Study type
Interventional
Enrollment
40 (actual)
First submitted
4 Nov 2022
Start date
20 Feb 2023
Primary completion date
25 Aug 2024
Lead sponsor
Rush University Medical Center
NCT number
NCT05630521

What you commit to

  • Study type: Interventional
  • Participants enrolled: 40
  • From 20 Feb 2023 to the primary completion date, 25 Aug 2024
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Acutely ill (e.g., symptoms of myocardial infarction, respiratory distress, stroke)
  • Patients who have end-stage renal disease (ESRD) and/or are on dialysis
  • Terminal chronic illness with a life expectancy of 6 months or less

Other

  • In state of hypertensive crisis (SBP \>180 and/or DBP \> 120 mmHg) at the time of study screening. Any participant in hypertensive crisis will be referred to their health care provider immediately for further instruction and follow-up, per current guidelines2
  • BP measurement is contraindicated on both upper extremities

Who the study is looking for

  • Aged ≥ 18 years at time of study entry
  • Able to read, write, and converse in English
  • Have an active prescription for at least one HTN medication, reporting no antihypertensive prescription changes for 30 days prior to study entry
  • Have prescription drug coverage or participate in a prescription assistance program that covers medication costs.
  • Diagnosis of HTN, based on self-report or confirmed through medical records, where available. (Self-reported high BP has long been shown to be strongly correlated with presence of a HTN diagnosis.22-24 Self-report combined with presence of a prescribed HTN medication ensures that only participants with HTN will be included)
  • Must self-administer their own medications
  • Uncontrolled BP: systolic (SBP) ≥ 130 mmHg and/or diastolic (DBP) ≥ 80 mmHg at baseline
  • Nonadherent to HTN medication (Hill-Bone Medication Subscale score \< 36) at screening

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Rush University Medical Center
Coordinator of this site? Confirm its status
ChicagoUnited StatesUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.